Figure 3

Intravenous C16 and Ang-1 enhanced the anti-inflammatory effects of PMSCs in rats with EAE as indicated in serum levels of TNF-α (A), IL-17 (B), IFN-γ (C) and TGF-β (D) at 3 and 8 weeks pi by ELISA. n = 5, ^#P < 0.05 vs. normal, ^*P < 0.05 vs. vehicle at 3 weeks pi, ^&P < 0.05 vs. PMSCs at 3 weeks pi, ^@P < 0.05 vs. vehicle at 8 weeks pi, ^$P < 0.05 vs. PMSCs at 8 weeks pi. (A) At 3 weeks pi, PMSCs vs. vehicle: ES = 0.33, P = 0.0001; P + C + A vs. vehicle: ES = 1.98, P < 0.0001; P + C + A vs. PMSCs: ES = 0.15, P = 0.004. AT 8 weeks pi, PMSCs vs. vehicle: ES = 0.45, P = 0.0003; P + C + A vs. vehicle: ES = 0.45, P < 0.0001; P + C + A vs. PMSCs: ES = 0.28, P = 0.003. (B) At 3 weeks pi, PMSCs vs. vehicle: ES = 3.895, P < 0.0001; P + C + A vs. vehicle: ES = 1.86, P < 0.0001; P + C + A vs. PMSCs: ES = 0.04, p = 0.22. AT 8 weeks pi, PMSCs vs. vehicle: ES = 0.2, P < 0.0001; P + C + A vs. vehicle: ES = 0.34, P < 0.0001; P + C + A vs. PMSCs: ES = 0.09, P = 0.03. (C) At 3 weeks pi, PMSCs vs. vehicle: ES = 0.9, P < 0.0001; P + C + A vs. vehicle: ES = 1.51, P < 0.0001); P + C + A vs. PMSCs: ES = 0.1, P = 0.09; At 8 weeks pi, PMSCs vs. vehicle: ES = 0.3, P = 0.028; P + C + A vs. vehicle: ES = 0.36, P < 0.0001; P + C + A vs. PMSCs: ES = 0.07, P = 0.15. (D) At 3 weeks pi, PMSCs vs. vehicle: ES = 3.22, P < 0.0001; P + C + A vs. vehicle: ES = 4, P < 0.0001; P + C + A vs. PMSCs: ES = 0.24, P = 0.008. At 8 weeks pi, PMSCs vs. vehicle: ES = 3.47, P < 0.0001; P + C + A vs. vehicle: ES = 3.31, P < 0.0001; P + C + A vs. PMSCs: ES = 0.36, P = 0.0003.